This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
G1 Therapeutics Beheer
Beheer criteriumcontroles 2/4
G1 Therapeutics' CEO is Jack Bailey, appointed in Jan 2021, has a tenure of 3.67 years. total yearly compensation is $3.25M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $1.40M. The average tenure of the management team and the board of directors is 3.7 years and 6 years respectively.
Belangrijke informatie
Jack Bailey
Algemeen directeur
US$3.3m
Totale compensatie
| Percentage CEO-salaris | 24.5% |
| Dienstverband CEO | 3.7yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 3.7yrs |
| Gemiddelde ambtstermijn bestuur | 6yrs |
Recente managementupdates
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$45m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$3m | US$795k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$78m |
| Mar 31 2023 | n/a | n/a | -US$126m |
| Dec 31 2022 | US$3m | US$764k | -US$148m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$171m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$9m | US$735k | -US$148m |
| Sep 30 2021 | n/a | n/a | -US$134m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$2m | n/a | -US$99m |
Compensatie versus markt: Jack's total compensation ($USD3.25M) is above average for companies of similar size in the US market ($USD2.42M).
Compensatie versus inkomsten: Jack's compensation has increased whilst the company is unprofitable.
CEO
Jack Bailey (59 yo)
3.7yrs
Tenure
US$3,250,658
Compensatie
Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$3.25m | 0.37% $ 1.4m | |
| Chief Medical Officer | 10.2yrs | US$1.11m | 0.17% $ 625.3k | |
| Chief Business Officer | 5.2yrs | US$1.17m | 0.049% $ 186.1k | |
| Chief Financial Officer | 1.5yrs | geen gegevens | 0.037% $ 138.2k | |
| Chief Operating Officer | 5.7yrs | US$2.75m | 0.040% $ 151.2k | |
| Vice President of Investor Relations & Corporate Communications | 3.7yrs | geen gegevens | geen gegevens | |
| Chief Legal & People Officer | 1.3yrs | geen gegevens | 0.013% $ 49.0k | |
| Vice President of Marketing | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 3.1yrs | US$3.39m | 0.027% $ 101.8k | |
| Senior Director of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens |
3.7yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: GTHX's management team is considered experienced (3.7 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 4.5yrs | US$3.25m | 0.37% $ 1.4m | |
| Member of Clinical Advisory Board | no data | US$456.29k | geen gegevens | |
| Independent Director | 9yrs | US$172.85k | 0.35% $ 1.3m | |
| Scientific & Clinical Advisor | no data | geen gegevens | geen gegevens | |
| Scientific & Clinical Advisor | no data | geen gegevens | geen gegevens | |
| Independent Director | 6.3yrs | US$162.85k | 0.030% $ 113.6k | |
| Independent Chairman of the Board | 6yrs | US$195.35k | 0.027% $ 102.9k | |
| Scientific & Clinical Advisor | no data | geen gegevens | geen gegevens | |
| Director | 2.2yrs | US$135.35k | 0% $ 0 | |
| Co-Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Scientific & Clinical Advisor | no data | geen gegevens | geen gegevens | |
| Scientific & Clinical Advisor | no data | geen gegevens | geen gegevens |
6.0yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: GTHX's board of directors are considered experienced (6 years average tenure).